Latest Conference Articles

September 20th 2021, 9:42pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

September 20th 2021, 9:37pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

September 20th 2021, 9:25pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer. 

September 20th 2021, 9:23pm

International Workshop on CLL

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

September 20th 2021, 9:20pm

International Workshop on CLL

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

September 20th 2021, 8:13pm

International Workshop on CLL

A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.

September 20th 2021, 7:34pm

ESMO Congress

Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.

September 20th 2021, 7:24pm

International Workshop on CLL

Zanubrutinib monotherapy showed a deepening of response in patients with relapsed/refractory chronic lymphocytic leukemia.

September 20th 2021, 6:50pm

ESMO Congress

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

September 20th 2021, 4:57pm

ESMO Congress

First-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.

September 20th 2021, 4:39pm

International Workshop on CLL

TG-1701, a covalently bound BTK inhibitor, used as monotherapy or in combination with umbralisib and ublituximab, demonstrated promising activity and a manageable safety profile in patients with chronic lymphocytic leukemia.

September 19th 2021, 9:10pm

International Workshop on CLL

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.

September 19th 2021, 8:58pm

ESMO Congress

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

September 19th 2021, 8:10pm

ESMO Congress

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

September 19th 2021, 8:00pm

ESMO Congress

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.

September 19th 2021, 7:45pm

ESMO Congress

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

September 19th 2021, 7:42pm

ESMO Congress

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

September 19th 2021, 7:25pm

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

September 19th 2021, 6:57pm

ESMO Congress

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

September 19th 2021, 6:12pm

ESMO Congress

Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.